Company Overview of Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus (HCV), Influenza virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepatitis C viral replication. The co...
1860 Montreal Road
Tucker, GA 30084
Founded in 2007
Key Executives for Cocrystal Pharma, Inc.
Co-Founder, Vice Chairman and Interim Chief Executive Officer
Total Annual Compensation: $133.5K
Co-Founder and President
Total Annual Compensation: $203.6K
Interim Chief Financial Officer and Controller
Total Annual Compensation: $58.7K
General Counsel and Corporate Secretary
Total Annual Compensation: $132.8K
Compensation as of Fiscal Year 2015.
Cocrystal Pharma, Inc. Key Developments
Cocrystal Pharma, Inc. Announces Positive Interim Data from an Ongoing Phase 1 Study with CC-31244 for the Treatment of Chronic Hepatitis C Infection
Nov 7 16
Cocrystal Pharma, Inc. announced positive data from a randomized, double-blind Phase Ia/Ib study of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI), for the treatment of chronic hepatitis C virus (HCV) infection. The study is designed to evaluate CC-31244's safety/tolerability and pharmacokinetics, including food effect and antiviral activity. The study includes two groups: Group A (single ascending doses, and multiple doses in healthy volunteers), and Group B (multiple doses in HCV infected individuals). The study has dosed a total of 42 healthy volunteers with single (20, 50, 100, 200 and 400 mg) and multiple doses of CC-31244 at 200 and 400 mg for 7 days. Five HCV GT1 infected patients were dosed, four with 400 mg of CC-31244 once daily for 7 days and one with placebo. Data from the once daily 400 mg dosing arm demonstrate that CC-31244 had a substantial and durable antiviral effect with an average HCV RNA viral load decline from baseline of 3 log orders by 48 hours after dosing. The average viral load at 6 days post last dose remained on average 1.9 log orders below baseline. In addition, no viral breakthrough was observed during the treatment period. No serious adverse event was reported. CC-31244 is an investigational, oral, potent, pan-genotypic NNI with high barrier to drug resistance designed and developed using the company's proprietary structure-based drug discovery technology. The molecule interacts with the NS5B RNA polymerase of all major HCV genotypes.
Cocrystal Pharma, Inc. Presents at Ladenburg Thalmann 2nd Annual Healthcare Conference, Sep-27-2016 12:00 PM
Sep 1 16
Cocrystal Pharma, Inc. Presents at Ladenburg Thalmann 2nd Annual Healthcare Conference, Sep-27-2016 12:00 PM. Venue: The Sofitel New York, New York, New York, United States. Speakers: Gary L. Wilcox, Co-Founder, Vice Chairman, Interim Chief Executive Officer and Member of Scientific Review Committee.
Cocrystal Pharma, Inc. Announces Management Changes
Jul 22 16
Cocrystal Pharma, Inc. announced that Dr. Gary Wilcox will assume the role of interim Chief Executive Officer effective July 22, 2016. Dr. Wilcox previously served as the Chief Executive Officer of Cocrystal from 2008 to 2015. Mr. Jeffrey Meckler stepped down as Chief Executive Officer and from the Board to pursue other interests. Dr. Wilcox will continue to serve as the Vice Chairman of the Board of Directors of the company. In addition, Dr. Douglas Mayers, the Chief Medical Officer at Cocrystal, submitted his resignation effective immediately. Dr. Luz Pascual, Vice President Clinical Development, shall continue to oversee the ongoing clinical programs. Dr. Wilcox has over 35 years of experience in biotech companies including 14 years at Icos Corporation where he played a key role in the development of Cialis as the Executive Vice President of Operations and a member of the board of directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 1, 2016
August 17, 2016
March 14, 2016